Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 466.67% | -111.51% | 52.51% | -29.52% | -51.49% |
| Total Depreciation and Amortization | 12.08% | 6.47% | 4.54% | -6.26% | -0.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.48% | 342.70% | -165.45% | -2.18% | 124.05% |
| Change in Net Operating Assets | -306.14% | 340.18% | 28.90% | 81.36% | -36,474.07% |
| Cash from Operations | -97.89% | 21.64% | 6.96% | 360.17% | -126.48% |
| Capital Expenditure | 12.13% | -4.51% | -6.61% | 22.92% | -46.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | 90.68% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.93% | 783.90% | 23.00% | -1,520.48% | -104.76% |
| Cash from Investing | 62.56% | -131.21% | 20.93% | -575.41% | -108.44% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -306.50% | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -65.49% | 215.31% | 77.42% | -486.49% | -2,566.67% |
| Cash from Financing | -176.14% | 8,759.18% | 77.42% | -486.49% | 99.41% |
| Foreign Exchange rate Adjustments | 266.90% | -600.00% | -120.50% | -70.24% | 228.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -275.27% | -17.65% | 46.19% | -103.32% | -124.91% |